Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8<sup>+</sup> T cell control of tumor challenge in mice
These results suggest that the Ad26.VP22.7Epi vaccine led to improved tumor control compared with the peptide vaccine due to increased T cell hyperexpansion and functional activation. Our data suggest that future cancer vaccine development strategies should focus on inducing functional hyperexpanded CD8<sup>+</sup> T cell responses and not only maximizing tumor infiltrating CD8<sup>+</sup> T cell numbers.
Authors
- Alessandro Colarusso (ORCID: https://orcid.org/0000-0003-4612-4415)
- Victoria Giffin (ORCID: https://orcid.org/0000-0002-9783-302X)
- Tochi Anioke (ORCID: https://orcid.org/0000-0003-4523-4997)
- Malika Aïd (ORCID: https://orcid.org/0000-0002-4498-7893)
- Robert C. Patio (ORCID: https://orcid.org/0000-0002-5822-8337)
- Dan H. Barouch (ORCID: https://orcid.org/0000-0001-5127-4659)
- Gabriel Dagotto (ORCID: https://orcid.org/0000-0002-9872-6074)
- Trisha Anand (ORCID: https://orcid.org/0009-0009-7712-2915)
- David Li (ORCID: https://orcid.org/0000-0002-8921-5168)
- Ruoran Guan
- Esther R. Mbiwan (ORCID: https://orcid.org/0009-0001-2292-3741)
Institutions
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Ragon Institute of MGH, MIT and Harvard (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-009644
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.20
Funders
- Ragon Institute of MGH, MIT and Harvard